CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows:

• Cowen and Company 33^rd Annual Healthcare Conference on March 4, 2013, at 4:10pm ET in the Vineyard Room of the Boston Marriott Copley Place in Boston, MA. A breakout session will be held immediately following the presentation in the Yarmouth Room
• 24^th Annual Cancer Progress Conference on March 6, 2013, at 8:45am ET at the Conrad in New York, NY
• BIO-Europe Spring 2013 Conference on March 11, 2013, at 2:45pm CET at the CCIB Convention Centre in Barcelona, Spain
• 25^th Annual ROTH Conference on March 19, 2013, at 10:30am PT at the Ritz Carlton in Laguna Niguel, CA

A webcast of the Cowen and Company and ROTH conference presentations can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Investor contact:
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
or
Media contact:
Kari Watson, 781-235-3060
kwatson@macbiocom.com